Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity is related to high plasma tenofovir concentrations. Tenofovir alafenamide (TAF) is a tenofovir prodrug with 90% lower plasma tenofovir concentrations. The aim of this study was to evaluate changes in tenofovir-induced nephrotoxicity in Human Immunodeficiency Virus (HIV)-positive patients who switched from TDF to TAF. Materials and Methods: We identified all HIV-positive patients who switched from elvitegravir/cobicistat/emtricitabine/TDF to elvitegravir/cobicistat/emtricitabine/TAF at a tertiary hospital. We assessed tubulopathy and renal dysfunction before TDF administration, at the time TAF was used following at least 3 months of TDF use, and 3 months after TAF administration. Tubulopathy was defined by the presence of at least three abnormalities in fractional excretion of phosphate, fractional excretion of uric acid, urinary β2-microglobulin, urinary N-acetyl-β-D-glucosaminidase, glucosuria or proteinuria. Renal dysfunction was defined as decreased by more than 25% in the estimated glomerular filtration rate (eGFR) relative to baseline. Results: In 80 patients, the mean eGFR was 96.8 mL/min/1.73 m2 before administration of TDF, 81.2 (P <0.001) at the time of change to TAF, 90.9 (P <0.001) after TAF administration. Renal dysfunction occurred in 19 patients (23.8%) after TDF use for a median 15 months, 11 (57.9%) of these patients recovered from renal dysfunction after TAF administration. Six patients (7.5%) had tubulopathy before TDF administration, 36 (45.0%) after TDF administration (P <0.001), 12 (15.0%) after TAF administration (P = 0.002). Conclusion: Tenofovir-induced nephrotoxicity in HIV-positive patients receiving TDF was mostly reversible after changing to TAF. Thus, TAF-containing regimens can be administered safely to HIV-positive patients with tenofovir-induced nephrotoxicity.
Abstract
Background: Tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity is related to high plasma tenofovir concentrations. Tenofovir alafenamide (TAF) is a tenofovir prodrug with 90% lower plasma tenofovir concentrations. The aim of this study was to evaluate changes in tenofovir-induced nephrotoxicity in Human Immunodeficiency Virus (HIV)-positive patients who switched from TDF to TAF. Materials and Methods: We identified all HIV-positive patients who switched from elvitegravir/cobicistat/emtricitabine/TDF to elvitegravir/cobicistat/emtricitabine/TAF at a tertiary hospital. We assessed tubulopathy and renal dysfunction before TDF administration, at the time TAF was used following at least 3 months of TDF use, and 3 months after TAF administration. Tubulopathy was defined by the presence of at least three abnormalities in fractional excretion of phosphate, fractional excretion of uric acid, urinary β2-microglobulin, urinary N-acetyl-β-D-glucosaminidase, glucosuria or proteinuria. Renal dysfunction was defined as decreased by more than 25% in the estimated glomerular filtration rate (eGFR) relative to baseline. Results: In 80 patients, the mean eGFR was 96.8 mL/min/1.73 m2 before administration of TDF, 81.2 (P <0.001) at the time of change to TAF, 90.9 (P <0.001) after TAF administration. Renal dysfunction occurred in 19 patients (23.8%) after TDF use for a median 15 months, 11 (57.9%) of these patients recovered from renal dysfunction after TAF administration. Six patients (7.5%) had tubulopathy before TDF administration, 36 (45.0%) after TDF administration (P <0.001), 12 (15.0%) after TAF administration (P = 0.002). Conclusion: Tenofovir-induced nephrotoxicity in HIV-positive patients receiving TDF was mostly reversible after changing to TAF. Thus, TAF-containing regimens can be administered safely to HIV-positive patients with tenofovir-induced nephrotoxicity.
참고문헌 (25)
- Ryom L, "Highlights of the 2017 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons version 9.0", HIV Med, 19, pp.309~315 (2018)
- Molina JM, "On-demand preexposure prophylaxis in men at high risk for HIV-1 infection", N Engl J Med, 373, pp.2237~2246 (2015)
- Landovitz RJ, "Clinical practice. Postexposure prophylaxis for HIV infection", N Engl J Med, 361, pp.1768~1775 (2009)
- Verhelst D, "Fanconi syndrome and renal failure induced by tenofovir : a first case report", Am J Kidney Dis, 40, pp.1331~1333 (2002)
- Schaaf B, "Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome", Clin Infect Dis, 37, pp.e41~e43 (2003)
- Peyrière H, "Renal tubular dysfunction associated with tenofovir therapy : report of 7 cases", J Acquir Immune Defic Syndr, 35, pp.269~273 (2004)
- Cohen SD, "Kidney diseases associated with human immunodeficiency virus infection", N Engl J Med, 377, pp.2363~2374 (2017)
- Labarga P, "Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir", AIDS, 23, pp.689~696 (2009)
- Rodríguez-Nóvoa S, "Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir : a pharmacogenetic study", Clin Infect Dis, 48, pp.e108~e116 (2009)
- Cooper RD, "Systematic review and meta-analysis : renal safety of tenofovir disoproxil fumarate in HIV-infected patients", Clin Infect Dis, 51, pp.496~505 (2010)
- Walti LN, "Tenofovir alafenamide in multimorbid HIV-infected patients with prior tenofovir-associated renal toxicity", Open Forum Infect Dis, 5, pp.ofy275~ (2018)
- Jafari A, "Tenofovir-induced nephrotoxicity : incidence, mechanism, risk factors, prognosis and proposed agents for prevention", Eur J Clin Pharmacol, 70, pp.1029~1040 (2014)
- Sax PE, "Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection : two randomised, double-blind, phase 3, non-inferiority trials", Lancet, 385, pp.2606~2615 (2015)
- Arribas JR, "Brief report : randomized, double-blind comparison of tenofovir alafenamide(TAF)vs tenofovir disoproxil fumarate(TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine(E", C, J Acquir Immune Defic Syndr, pp.2017, 75[DOI]
- Pozniak A, "Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment : 48-week results from a single-arm, multicenter, open-label phase 3 study", J Acquir Immune Defic Syndr, 71, pp.530~537 (2016)
- Nishijima T, "Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection : a pharmacogenetic study", Clin Infect Dis, 55, pp.1558~1567 (2012)
- Chaisiri K, "Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight", Curr HIV Res, 8, pp.504~509 (2010)
- Nishijima T, "Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients : a retrospective cohort study of Japanese patients", PLoS One, 6, pp.e22661~ (2011)
- Günthard HF, "Antiretroviral treatment of adult HIV infection : 2014 recommendations of the International Antiviral Society-USA Panel", JAMA, 312, pp.410~425 (2014)
- World Health Organization(WHO), "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach", WHO, ~ (2016)
- Dragovic G, "Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country : a cohort study", BMC Infect Dis, 16, pp.106~ (2016)
- Hall AM, "Tenofovir-associated kidney toxicity in HIV-infected patients : a review of the evidence", Am J Kidney Dis, 57, pp.773~780 (2011)
- Suzuki S, "Effect of tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-naïve asian patients : results from 12-year observational cohort", AIDS Patient Care STDS, 31, pp.105~112 (2017)
- Nishijima T, "Renal function declines more in tenofovir-than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection", PLoS One, 7, pp.e29977~ (2012)
- Rodríguez-Nóvoa S, "Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations", AIDS, 24, pp.1064~1066 (2010)